Feedback  丨  Language:简体中文English


Home 丨  About Us 丨  News Center 丨  Industry News 丨  Research Progress  丨  Contact Us
Address: 117 Yangxiang, Wuxi, Jiangsu, P.R.China  Zip:214064
Copyright:Jiangsu Institute of Parasitic Diseases (JIPD)    
苏ICP备11056399号   Powered by www.300.cn 

Short Report Blood Stage of Plasmodium vivax in Central China Is Still Susceptible

[Abstract]:
IncentralChina,Plasmodiumvivaxaccountsforallofthenativereportedcasesofmalaria.Chloroquine(CQ)plusprimaquine(PQ)havebeenusedformorethan60yearsasthefrontlinedrugs,buttheriskoftreatmentfailure remainsunk
In central China, Plasmodium vivax accounts for all of the native reported cases of malaria. Chloroquine(CQ) plus primaquine (PQ) have been used for more than 60 years as the frontline drugs, but the risk of treatment failure remains unknown. To measure the effectiveness and safety of CQ-PQ among vivax malaria patients, a total of 39 subjects with monoinfection vivax malaria was enrolled in a study from 2008 to 2009. There were no recrudescence or danger signs observed within the 28-day follow-up period, showing that blood stage of P. vivax isolates from central China is still
susceptible to CQ plus PQ combination therapy. However, the antirelapse efficacy of PQ is difficult to assess because of the high rate of loss to follow-up after 28 days; also, parasites persisted in a single case at 3 days post-antimalarial drug
treatment, indicating that continuous annual monitoring is needed in central China.